J&J/DePuy Charité Artificial Spinal Disc Unanimously Backed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/DePuy Spine should collect two years of postmarket follow-up data on Charité artificial lumbar disc recipients, according to FDA's Orthopaedic & Rehabilitation Devices Panel
You may also be interested in...
Swift FDA Approval Can Complicate Reimbursement Efforts, Consultant Says
Rapid FDA approval of Johnson & Johnson/Depuy's Charité artificial disc contributed to early reimbursement setbacks for the device, according to Quorum Consulting Senior Consultant Barbara Santry
Swift FDA Approval Can Complicate Reimbursement Efforts, Consultant Says
Rapid FDA approval of Johnson & Johnson/Depuy's Charité artificial disc contributed to early reimbursement setbacks for the device, according to Quorum Consulting Senior Consultant Barbara Santry
Archus Receives FDA Green Light To Initiate First Spinal Facet Implant Trial
Archus Orthopedics' March 28 receipt of investigational device exemption approval for its Total Facet Arthroplasty System for treating spinal stenosis furthers the firm's first-to-market goal